

# Prakash Deedwania

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11879782/publications.pdf>

Version: 2024-02-01

74  
papers

9,526  
citations

94433

37  
h-index

79698

73  
g-index

76  
all docs

76  
docs citations

76  
times ranked

10879  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
2	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. <i>JAMA Cardiology</i> , 2021, 6, 139.	6.1	50
3	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , 2021, 134, e252-e263.	1.5	14
4	Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100055.	2.2	7
5	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019, 13, 586-593.e5.	1.5	11
6	Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. <i>Indian Heart Journal</i> , 2019, 71, 309-313.	0.5	110
7	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 288.	6.1	93
8	Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. <i>European Journal of Heart Failure</i> , 2018, 20, 359-369.	7.1	17
9	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines® Coronary Artery Disease (GWTG-CAD) program. <i>American Heart Journal</i> , 2017, 187, 78-87.	2.7	17
10	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	2.3	5
11	Anticoagulation in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 786-788.	2.8	4
12	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 941-950.	11.4	452
13	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. <i>International Journal of Cardiology</i> , 2017, 227, 462-466.	1.7	16
14	Mechanical Circulatory Support and Rationale for Future Research Reply. <i>JAMA Internal Medicine</i> , 2016, 176, 715.	5.1	0
15	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. <i>Current Hypertension Reports</i> , 2016, 18, 76.	3.5	51
16	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <i>Core Evidence</i> , 2015, 10, 63.	4.7	2
17	Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. <i>American Journal of Medicine</i> , 2015, 128, 715-721.	1.5	36
18	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. <i>Circulation: Heart Failure</i> , 2015, 8, 17-24.	3.9	11

#	ARTICLE	IF	CITATIONS
19	Is Increased Use of Mechanical Circulatory Support Devices Justified?. JAMA Internal Medicine, 2015, 175, 1982.	5.1	2
20	The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. Expert Opinion on Drug Safety, 2015, 14, 1855-1863.	2.4	11
21	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. Circulation, 2015, 132, 691-718.	1.6	303
22	Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation. American Journal of Cardiology, 2015, 116, 1852-1857.	1.6	56
23	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. International Journal of Angiology, 2015, 24, 105-112.	0.6	3
24	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	8.6	346
25	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	1.5	31
26	Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease. American Journal of Medicine, 2015, 128, 219-228.	1.5	161
27	Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. Indian Heart Journal, 2014, 66, 280-288.	0.5	40
28	Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 945-952.	3.9	32
29	Racial differences in mortality in patients with advanced systolic heart failure: Potential role of right ventricular ejection fraction. International Journal of Cardiology, 2014, 177, 255-260.	1.7	1
30	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.	1.6	5
31	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation: Cardiovascular Genetics, 2012, 5, 51-57.	5.1	21
32	β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	7.4	377
33	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. Circulation, 2012, 125, 1979-1987.	1.6	149
34	Regional variations in cardiovascular risk factors in India: India heart watch. World Journal of Cardiology, 2012, 4, 112.	1.5	164
35	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. Core Evidence, 2012, 7, 49.	4.7	12
36	An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. Reviews in Cardiovascular Medicine, 2012, 13, e89-104.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 137-156.	2.2	40
38	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. <i>Cardiology Clinics</i> , 2011, 29, 87-103.	2.2	37
39	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. <i>Cardiology Clinics</i> , 2011, 29, 47-70.	2.2	19
40	Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating $\beta$ -Blockers. <i>Journal of Clinical Hypertension</i> , 2011, 13, 52-59.	2.0	66
41	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. <i>American Journal of Cardiology</i> , 2011, 107, 1208-1214.	1.6	92
42	A Propensity-Matched Study of the Association of Diabetes Mellitus With Incident Heart Failure and Mortality Among Community-Dwelling Older Adults. <i>American Journal of Cardiology</i> , 2011, 108, 1747-1753.	1.6	11
43	Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. <i>European Journal of Heart Failure</i> , 2011, 13, 200-206.	7.1	87
44	Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). <i>American Journal of Cardiology</i> , 2010, 106, 221-227.	1.6	44
45	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	27.0	588
46	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	27.0	430
47	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , 2009, 5, 495.	2.3	6
48	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Circulation</i> , 2009, 119, 351-357.	1.6	308
49	An Overview of Glycemic Control in the Coronary Care Unit with Recommendations for Clinical Management. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1342-1351.	2.2	15
50	Usefulness of Abnormal Heart Rate Turbulence to Predict Cardiovascular Mortality in High-Risk Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction (from the EPHEBUS) <i>Tj ETQqO 0 0 rgBT 10verlock 20 Tf 50 2</i>	1.6	18
51	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. <i>American Journal of Cardiology</i> , 2009, 104, 3E-9E.	1.6	18
52	The endocannabinoid system and cardiometabolic risk: Effects of CB1 receptor blockade on lipid metabolism. <i>International Journal of Cardiology</i> , 2009, 131, 305-312.	1.7	8
53	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Journal of the American College of Cardiology</i> , 2009, 53, 298-304.	2.8	373
54	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 210-220.	2.3	15

#	ARTICLE	IF	CITATIONS
55	Ambulatory ECG-Based T-wave Alternans Predicts Sudden Cardiac Death in High-Risk Post-MI Patients with Left Ventricular Dysfunction in the EPHEBUS Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 1037-1042.	1.7	83
56	Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1448-1454.	2.8	291
57	Hyperglycemia and Acute Coronary Syndrome. <i>Circulation</i> , 2008, 117, 1610-1619.	1.6	397
58	Diabetes and vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 127-138.	1.5	17
59	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. <i>Circulation</i> , 2008, 117, 3002-3009.	1.6	405
60	Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1131-1139.	4.5	246
61	Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 700-707.	1.6	213
62	Evolving Treatment Options for Prevention of Cardiovascular Events in High-Risk Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2007, 9, 883-888.	2.0	7
63	Management of coronary artery disease in patients with type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , 2007, 9, 264-271.	2.9	7
64	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Lancet, The</i> , 2006, 368, 919-928.	13.7	369
65	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006, 29, 1220-1226.	8.6	493
66	What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?. <i>Journal of the American College of Cardiology</i> , 2005, 45, 252-259.	2.8	96
67	How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 264-275.	1.0	13
68	Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222</i>	1.6	24
69	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. <i>Journal of the American College of Cardiology</i> , 2003, 42, 914-922.	2.8	198
70	A comparative analysis of the results from 4 trials of $\beta^2$ -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. <i>Journal of Cardiac Failure</i> , 2003, 9, 354-363.	1.7	164
71	Tolerability of $\beta^2$ -Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). <i>Circulation</i> , 2002, 105, 1182-1188.	1.6	87
72	Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. <i>American Heart Journal</i> , 2001, 142, 502-511.	2.7	115

#	ARTICLE	IF	CITATIONS
73	Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2000, 283, 1295.	7.4	1,193
74	Sotalol. Drugs, 1987, 34, 311-349.	10.9	86